Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women.

@article{Cunningham2001SafetyO2,
  title={Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women.},
  author={Coleen K. Cunningham and Diane W. Wara and Minhee Kang and Terence Fenton and Elizabeth M. Hawkins and James Mcnamara and Lynne Mofenson and Anne Marie Duliege and Damon Francis and Elizabeth J. McFarland and William Borkowsky},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2001},
  volume={32 5},
  pages={801-7}
}
To determine the safety of 2 candidate vaccines against human immunodeficiency virus type 1 (HIV-1), a randomized, placebo-controlled, multicenter trial compared low, medium, and high doses of the vaccines or an adjuvant among infants born to HIV-infected women. No local or systemic reactions of grade 2 or greater were reported 48 h after the subjects underwent immunization. Grade 3 or 4 chemistry toxicities occurred in 5 (3%) and grade 3 or 4 hematologic toxicities in 17 (11%) of 154… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Similar Papers

Loading similar papers…